Suivre
Buyck Julien
Buyck Julien
Inserm U 1070
Adresse e-mail validée de univ-poitiers.fr
Titre
Citée par
Citée par
Année
Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and …
JM Buyck, P Plésiat, H Traore, F Vanderbist, PM Tulkens, F Van Bambeke
Clinical Infectious Diseases 55 (4), 534-542, 2012
1062012
Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes
JM Buyck, PM Tulkens, F Van Bambeke
Antimicrobial agents and chemotherapy 57 (5), 2310-2318, 2013
642013
Outer membrane permeability: Antimicrobials and diverse nutrients bypass porins in Pseudomonas aeruginosa
J Ude, V Tripathi, JM Buyck, S Söderholm, O Cunrath, J Fanous, B Claudi, ...
Proceedings of the National Academy of Sciences 118 (31), e2107644118, 2021
632021
New amphiphilic neamine derivatives active against resistant Pseudomonas aeruginosa and their interactions with lipopolysaccharides
G Sautrey, L Zimmermann, M Deleu, A Delbar, L Souza Machado, ...
Antimicrobial agents and chemotherapy 58 (8), 4420-4430, 2014
572014
Quantitative contribution of efflux to multi-drug resistance of clinical Escherichia coli and Pseudomonas aeruginosa strains
O Cunrath, DM Meinel, P Maturana, J Fanous, JM Buyck, P Saint Auguste, ...
EBioMedicine 41, 479-487, 2019
452019
Salicylidene acylhydrazides and hydroxyquinolines act as inhibitors of type three secretion systems in Pseudomonas aeruginosa by distinct mechanisms
A Anantharajah, JM Buyck, C Sundin, PM Tulkens, MP Mingeot-Leclercq, ...
Antimicrobial agents and chemotherapy 61 (6), 10.1128/aac. 02566-16, 2017
402017
Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas aeruginosa Pathogenicity and Inflammasome Activation
A Anantharajah, E Faure, JM Buyck, C Sundin, T Lindmark, J Mecsas, ...
The Journal of infectious diseases 214 (7), 1105-1116, 2016
322016
Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1β secretion in a model of human THP-1 …
A Anantharajah, JM Buyck, E Faure, Y Glupczynski, ...
Pathogens and disease 73 (7), ftv049, 2015
282015
Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from …
JM Buyck, S Guénard, P Plésiat, PM Tulkens, F Van Bambeke
Journal of antimicrobial chemotherapy 67 (3), 771-775, 2012
282012
Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes
JM Buyck, PM Tulkens, F Van Bambeke
Antimicrobial agents and chemotherapy 59 (1), 258-268, 2015
262015
P. aeruginosa LPS stimulates calcium signaling and chloride secretion via CFTR in human bronchial epithelial cells
JM Buyck, V Verriere, R Benmahdi, G Higgins, B Guery, R Matran, ...
Journal of Cystic Fibrosis 12 (1), 60-67, 2013
242013
Clinical pharmacokinetics of daptomycin
N Gregoire, A Chauzy, J Buyck, B Rammaert, W Couet, S Marchand
Clinical Pharmacokinetics 60 (3), 271-281, 2021
232021
Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii
V Aranzana-Climent, JM Buyck, Y Smani, J Pachón-Diaz, S Marchand, ...
Clinical Microbiology and Infection 26 (9), 1254. e9-1254. e15, 2020
232020
Caspase-1-driven neutrophil pyroptosis and its role in host susceptibility to Pseudomonas aeruginosa
K Santoni, D Pericat, L Gorse, J Buyck, M Pinilla, L Prouvensier, ...
PLoS pathogens 18 (7), e1010305, 2022
222022
In vitro models for the study of the intracellular activity of antibiotics
JM Buyck, S Lemaire, C Seral, A Anantharajah, F Peyrusson, PM Tulkens, ...
Bacterial Persistence: Methods and Protocols, 147-157, 2016
132016
Semimechanistic Pharmacodynamic Modeling of Aztreonam‐Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug‐Resistant Gram‐Negative Bacteria
A Chauzy, B Gaelzer Silva Torres, J Buyck, B de Jonge, C Adier, ...
CPT: pharmacometrics & systems pharmacology 8 (11), 815-824, 2019
112019
Preclinical pharmacokinetic and pharmacodynamic data to support cefoxitin nebulization for the treatment of Mycobacterium abscessus
S Mehta, V Aranzana-Climent, B Rammaert, N Grégoire, S Marchand, ...
Antimicrobial agents and chemotherapy 63 (7), 10.1128/aac. 02651-18, 2019
102019
Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam–avibactam
A Chauzy, J Buyck, BLM de Jonge, S Marchand, N Grégoire, W Couet
Clinical Microbiology and Infection 25 (4), 515. e1-515. e4, 2019
102019
Bacterial Persistence: Methods and Protocols
J Michiels, M Fauvart
Humana Press, 2016
92016
Sequential time-kill, a simple experimental trick to discriminate between pharmacokinetics/pharmacodynamics models with distinct heterogeneous subpopulations versus homogenous …
A Chauzy, H Ih, M Jacobs, S Marchand, N Grégoire, W Couet, JM Buyck
Antimicrobial Agents and Chemotherapy 64 (8), 10.1128/aac. 00788-20, 2020
82020
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20